Published: 17 January 2022
Author(s): Paola Rebora, Marco Centola, Nuccia Morici, Alice Sacco, Giuseppe Occhino, Giovanna Viola, Jacopo Oreglia, Diego Castini, Simone Persampieri, Ludovico Sabatelli, Giulia Ferrante, Stefano Lucreziotti, Stefano Carugo, Maria Grazia Valsecchi, Fabrizio Oliva, Cristina Giannattasio, Alessandro Maloberti
Issue: May 2022
Section: Original article

Uric Acid (UA) has been related to the development of fatal and non-fatal Cardio-Vascular (CV) events in the general population [1] as well as in patients experiencing an Acute Coronary Syndromes (ACS) [2] and in those affected by Heart Failure (HF) [3]. In this latter group, results were also confirmed in the context of acute decompensated HF with a significant relationship between UA, measured at the time of admission, and subsequent long-term mortality and re-hospitalization [4]. Furthermore, UA was also associated with the development of new-onset HF [5] and with a lower Left Ventricular Ejection Fraction (LVEF) and exercise capacity and a higher NYHA class [6].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.